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The organophosphorus pesticide chlorpyrifos
(CPF) remains in use throughout the world
despite its recent curtailment in the United
States [U.S. Environmental Protection Agency
(EPA) 2000, 2002]. The major concern for
CPF is its propensity to elicit developmental
neurotoxicity at exposure levels below the
threshold for systemic toxicity, such that dam-
aging exposures of pregnant women and chil-
dren may go undetected because of the lack of
symptoms (Landrigan 2001; Landrigan et al.
1999; May 2000; Physicians for Social
Responsibility 1995; Pope 1999; Slotkin
1999, 2004; Weiss et al. 2004). CPF was
originally thought to exert adverse effects on
brain development through the same mecha-
nism by which it elicits systemic toxicity,
namely, inhibition of cholinesterase through
its active metabolite, CPF oxon, but it is now
evident that other, noncholinergic mecha-
nisms participate in its developmental neuro-
toxicity (Barone et al. 2000; Clegg and van
Gemert 1999a, 1999b; Gupta 2004; Mileson
et al. 1998; Pope 1999; Slotkin 1999, 2004).
Even at exposures below the threshold for
cholinesterase inhibition, CPF itself disrupts
the patterns of neural cell replication and dif-
ferentiation, axonogenesis and synaptogenesis,
and the functional development of neuro-
transmitter and neurotrophin systems, culmi-
nating in aberrant behavioral performance
(Barone et al. 2000; Casida and Quistad
2004; Gupta 2004; Pope 1999; Qiao et al.
2002, 2003; Yanai et al. 2002). Consequently,
CPF-induced damage extends beyond cholin-
ergic pathways to include other neuro-
transmitter systems, notably the monoamines,
norepinephrine, dopamine (DA), and sero-
tonin (5HT), and recent studies show that
5HT systems are especially sensitive (Aldridge
et al. 2003, 2004, 2005a, 2005b; Raines et al.
2001; Sachana et al. 2001).
In recent work we found that, during a
critical developmental window centered
around the immediate perinatal period, CPF
elicits immediate and persistent effects on
expression of 5HT receptors and the 5HT
transporter, biomarkers for 5HT synaptic
development and integrity (Aldridge et al.
2003, 2004, 2005a; Raines et al. 2001).
Additionally, we found that the same expo-
sures elicited lasting changes in 5HT-related
behaviors, resembling animal models of
depression (Aldridge et al. 2005a). Notably,
these studies were conducted spanning CPF
exposures below the threshold for observable
toxicity and, more important, could be
detected at doses devoid of cholinesterase inhi-
bition in the developing brain (Qiao et al.
2002). In the present study, we assessed 5HT
levels and turnover, a measure of synaptic activ-
ity, in adulthood after prenatal or neonatal
CPF exposure in order to provide a mechanistic
link between effects on static biomarkers of
5HT synaptic development and altered behav-
ior. Measurements were conducted using the
metabolite ratio method (Slotkin et al. 2000;
Xu et al. 2001), assessing the relative amounts
of 5HT and its metabolite 5-hydroxyindole-
acetic acid (5HIAA), with turnover calculated
as the 5HIAA:5HT ratio. We examined brain
regions with prominent 5HT innervation that
are known to be targets for CPF (Aldridge
et al. 2003, 2004, 2005b; Raines et al. 2001).
CPF exposure was carried out during the
immediate perinatal period, the phase in
which the receptor and transporter biomarkers
indicate high susceptibility, or at a later post-
natal development period in which these
effects wane: exposure on gestational days
(GD) 17–20 and postnatal days (PN) 1–4 and
PN11–14 (Aldridge et al. 2003, 2004, 2005b;
Raines et al. 2001). Finally, effects on 5HT
systems were contrasted to those on DA levels
and turnover, again using the metabolite
ratio method (Slotkin et al. 2000; Xu et al.
2001), assessing dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA), cal-
culating the ratio as [DOPAC + HVA]:DA.
Materials and Methods
Animal treatments. All experiments using live
animals were carried out in accordance with
the Declaration of Helsinki (World Medical
Association 2004) and with the Guide for the
Care and Use of Laboratory Animals as adopted
and promulgated by the National Institutes of
Health (Institute of Laboratory Animal
Resources 1996). Timed-pregnant Sprague-
Dawley rats (Zivic Laboratories, Pittsburgh,
PA, USA) were housed in breeding cages, with
a 12-hr light/dark cycle and with free access to
food and water. CPF (Chem Service, West
Chester, PA, USA) was dissolved in dimethyl
sulfoxide to provide consistent absorption
(Whitney et al. 1995) and was injected subcu-
taneously in a volume of 1 mL/kg body
weight; control animals received equivalent
dimethyl sulfoxide vehicle injections. 
For exposure on GD17–20, dams were
injected daily with CPF at 1 and 5 mg/kg
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Exposure to chlorpyrifos (CPF) alters neuronal development of serotonin (5HT) and dopamine
systems, and we recently found long-term alterations in behaviors related to 5HT function. To
characterize the synaptic mechanisms underlying these effects, we exposed developing rats to CPF
regimens below the threshold for systemic toxicity, in three treatment windows: gestational days
(GD) 17–20, postnatal days (PN) 1–4, or PN11–14. In early adulthood (PN60), we assessed basal
neurotransmitter content and synaptic activity (turnover) in brain regions containing the major
5HT and dopamine projections. CPF exposure on GD17–20 or PN1–4 evoked long-term
increases in 5HT turnover across multiple regions; the effects were not secondary to changes in
neurotransmitter content, which was unaffected or even decreased. When the treatment window
was shifted to PN11–14, there were no long-term effects. Dopamine turnover also showed signiﬁ-
cant increases after CPF exposure on GD17–20, but only when the dose was raised above the
threshold for overt toxicity; however, hippocampal dopamine content was profoundly subnormal
after exposures below or above the acute, toxic threshold, suggesting outright neurotoxicity. These
results indicate that, in a critical developmental period, apparently nontoxic exposures to CPF pro-
duce lasting activation of 5HT systems in association with 5HT-associated behavioral anomalies.
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Researchbody weight, doses that span the threshold for
inhibition of fetal brain cholinesterase activity,
fetal growth impairment, and reduced mater-
nal weight gain, all of which become evident
at ≥ 5 mg/kg (Garcia et al. 2003; Qiao et al.
2002). On the day of birth, all pups were ran-
domized within their respective treatment
groups and redistributed to the dams with a
litter size of 10 to maintain a standard nutri-
tional status. Randomization was repeated at
intervals of 3 days, and in addition, within
each treatment group, dams were rotated
among litters to distribute any maternal care-
taking differences randomly. Animals were
weaned on PN21. On PN60, one male and
one female were selected from each litter and
were decapitated. The cerebellum, including
ﬂocculi, was removed, and the forebrain was
separated from the midbrain and brainstem by
a cut made rostral to the thalamus. The fore-
brain was then further dissected into the
regions containing major 5HT projections
(cerebral cortex, hippocampus, striatum), and
the midbrain and brainstem, which contain
the preponderance of 5HT cell bodies, were
separated from each other. The cerebellum,
which is sparse in 5HT neurons or projec-
tions, was not evaluated. Tissues were frozen
with liquid nitrogen and stored at –45°C.
For studies of CPF effects in the ﬁrst few
days after birth, animals were given a subcuta-
neous injection of 1 mg/kg daily on PN1–4;
for studies in older animals, which tolerate
higher doses (Campbell et al. 1997; Pope and
Chakraborti 1992; Pope et al. 1991; Whitney
et al. 1995), daily treatment with 5 mg/kg was
given on PN11–14. The same randomization
procedure was followed as described for pre-
natal CPF treatment. Neither regimen evoked
weight loss or mortality (Campbell et al. 1997;
Dam et al. 1998; Johnson et al. 1998; Song
et al. 1997). Samples were obtained on PN60
as described above.
Assays. Tissues were thawed and homoge-
nized in ice-cold 0.1 M perchloric acid and
sedimented for 20 min at 18,000 × g. The
supernatant solution was collected, and
aliquots were used for analysis of 5HT,
5HIAA, DA, HVA, and DOPAC by HPLC
with electrochemical detection (Slotkin et al.
2000; Xu et al. 2001). Concurrently run stan-
dards, containing each of the neurotransmitters
and metabolites (Sigma Chemical Co., St.
Louis, MO, USA), were used to calculate the
regional content of each neurochemical.
DOPAC and HVA levels in the hippocampus
were too low for accurate measurement.
Transmitter levels were calculated as nano-
grams per region, and, because there were no
treatment-related differences in brain region
weights, the same effects were obtained with
calculation as nanograms per gram of tissue or
per milligram of protein (data not shown).
Similarly, because 5HT and DA turnover were
calculated as ratios of metabolites to transmit-
ter, the values are independent of whether
region, tissue weight, or protein concentration
is used as the denominator term.
Data analysis. Each treatment group com-
prised six males and six females. We compiled
data as means ± SEs, and treatment-related dif-
ferences were assessed by analysis of variance
(ANOVA), with data log-transformed because
of heterogeneous variance, incorporating fac-
tors of treatment (control, CPF), brain region,
and sex. Where the initial test identiﬁed inter-
actions of CPF treatment with region, we sub-
divided the effects into the individual brain
regions and conducted lower-order tests to
examine treatment and sex differences.
Similarly, where ANOVA identified inter-
actions of CPF with sex, we subdivided data to
examine males and females separately. After
subdivisions, we used Fisher’s protected least
significant difference to evaluate differences
between individual groups. However, where
CPF treatment did not interact with other
variables, we assessed only the main treatment
effect. Signiﬁcance was assumed at the level of
p < 0.05 for main effects; however, for inter-
actions at p < 0.1, we examined lower-order
main effects after subdivision of the interactive
variables (Snedecor and Cochran 1967).
To facilitate comparison of treatment
effects across regions with widely differing
transmitter levels or turnovers, some results
are presented as the percentage change from
control values. However, statistical evalua-
tions were always conducted on the original
data. Similarly, for convenience, control val-
ues for the three different treatment regimens
were combined for presentation, but compari-
sons of CPF effects were conducted only with
the appropriately matched control cohort. For
reference, control values appear in Table 1.
Results
In brain regions of control rats, levels of 5HT,
DA, and their metabolites showed few sex dif-
ferences (Table 1). 5HIAA was slightly higher
in the striatum and midbrain of females,
whereas DA levels were lower in midbrain and
brainstem. None of the prenatal or postnatal
treatment regimens evoked signiﬁcant deﬁcits
in brain region weights (data not shown).
CPF exposure on GD17–20. Across all
brain regions, late gestational exposure to CPF
elicited a significant net overall reduction
(main treatment effect) in 5HT levels
(Figure 1A). However, the effect was seen only
at the higher dose (5 mg/kg), which elicits
maternal weight deficits and significant fetal
brain cholinesterase inhibition (Garcia et al.
2003; Qiao et al. 2002). Superimposed on the
main treatment effect, there were regional dif-
ferences: most regions showed a decrease in
content, but values increased in the striatum.
The pattern of effects on 5HT turnover was
unrelated to the effects on 5HT content, with
a main treatment effect representing a net
Aldridge et al.
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Table 1. Neurotransmitter and metabolite levels (ng/region) in control rat brain regions.
Brain region Sex 5HT 5HIAA DA DOPAC HVA
Cerebral cortex Male 267 ± 6 186 ± 5 243 ± 9 59 ± 2 42 ± 2
Female 255 ± 5 197 ± 5 230 ± 12 56 ± 2 42 ± 2
Hippocampus Male 113 ± 3 190 ± 5 1.3 ± 0.2 BD BD
Female 114 ± 3 202 ± 5 1.2 ± 0.2 BD BD
Striatum Male 165 ± 4 210 ± 5 541 ± 13 203 ± 7 55 ± 2
Female 173 ± 4 231 ± 5* 470 ± 13* 189 ± 6 50 ± 2
Midbrain Male 487 ± 15 299 ± 9 31 ± 1 16.1± 0.8 BD
Female 461 ± 13 324 ± 7* 26 ± 1* 14.1 ± 0.5 BD
Brainstem Male 189 ± 10 91 ± 6 4.0 ± 0.2 2.2 ± 0.2 BD
Female 188 ± 8 97 ± 7 3.4 ± 0.1* 2.2 ± 0.2 BD
BD, below detection limit. 
*Signiﬁcant sex differences.
Figure 1. Effects of GD17–20 CPF exposure on (A) 5HT content and (B) turnover. ANOVA across treatment,
region, and sex: (A), treatment, p < 0.03; control versus 5 mg/kg, p < 0.03; (B), treatment, p < 0.007; control
versus 1 mg/kg, p < 0.05; control versus 5 mg/kg, p < 0.002. Separate ANOVAs were not conducted for each
region because of the absence of treatment × region interactions. Similarly, values are shown combined
for males and females because of the lack of treatment × sex interactions.
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)increase (Figure 1B). In this case, however,
effects were statistically significant at both
1 and 5 mg/kg, thus indicating increased 5HT
turnover even at CPF exposures below the
threshold for maternal toxicity or fetal brain
cholinesterase inhibition. Again, some regions
(hippocampus, brainstem) showed much
larger changes than the others, particularly
compared with the striatum.
The pattern of effects on DA levels and
turnover differed substantially from those seen
for 5HT. Although DA content was unaffected
in most brain regions, there were massive
deﬁcits in the hippocampus with either the low
or high dose of CPF (Figure 2A). DA turnover
was affected only at the higher dose, with sig-
niﬁcant elevations in cerebral cortex, striatum,
and midbrain (Figure 2B); DA turnover could
not be assessed in the hippocampus because of
the low levels of DA metabolites.
CPF exposure on PN1–4. With early post-
natal treatment, CPF elicited sex-selective
alterations in 5HT content (Figure 3A). Males
showed no signiﬁcant change, whereas females
showed a small but statistically signiﬁcant net
decrease. Again, the effects on 5HT turnover
appeared to be unrelated to changes in 5HT
content, displaying a net increase that was not
sex selective and with the smallest magnitude
of effect in the striatum (Figure 3B).
Effects on DA levels and turnover after
CPF exposure on PN1–4 have appeared previ-
ously (Slotkin et al. 2002), exhibiting decreases
in cerebrocortical DA content and turnover,
increases in both parameters in the striatum,
and increased turnover in the midbrain.
CPF exposure on PN11–14. Despite the
use of a higher dose (5 mg/kg compared with
1 mg/kg on PN1–4) and the resultant greater
degree of cholinesterase inhibition (Qiao et al.
2002; Song et al. 1997), CPF exposure dur-
ing this later postnatal period had no signiﬁ-
cant effect on either 5HT content (Figure 4A)
or turnover (Figure 4B). Earlier work for DA
similarly found no alterations in either levels
or turnover (Slotkin et al. 2002).
Discussion
In earlier work, we found that CPF exposure
during a discrete developmental period in late
gestation and early neonatal life elicits lasting
up-regulation of the expression of 5HT
synaptic proteins, including 5HT1A and
5HT2 receptors and the presynaptic, high-
affinity 5HT transporter (Aldridge et al.
2004). The present results indicate that these
changes in static 5HT biomarkers are associ-
ated with functional changes in 5HT levels,
and, more important, in 5HT turnover, a
dynamic index of synaptic activity. Moreover,
the critical period for the alterations of trans-
mitter turnover seen here corresponds precisely
to that identified previously for the protein
biomarkers, with closure of the window of
vulnerability by the second postnatal week. In
both cases, it is of critical importance that the
lasting effects on 5HT function are elicited at
CPF exposures below the threshold for sys-
temic toxicity and even below that required
for inhibition of fetal brain cholinesterase.
The main findings here thus reinforce the
idea that cholinesterase inhibition per se is an
inadequate indicator of thresholds for CPF-
induced developmental neurotoxicity.
The increase in 5HT turnover evoked by
CPF exposure on either GD17–20 or PN1–4
is indicative of presynaptic hyperactivity, a
particularly striking finding in light of the
up-regulation of 5HT receptors evoked by the
same treatments (Aldridge et al. 2004).
Ordinarily, increased 5HT concentrations in
the synapse can be expected to evoke receptor
down-regulation as a compensation for over-
stimulation. As an initial impression, our
ﬁnding of global presynaptic/postsynaptic up-
regulation (receptors, transporter, turnover)
might then suggest an overwhelming increase
in 5HT function. However, evaluations of
5HT-linked behaviors and cell signaling both
indicate quite the opposite, namely, deﬁcien-
cies in 5HT function (Aldridge et al. 2004,
2005a). Accordingly, “miswiring” of 5HT
Developmental chlorpyrifos exposure
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Figure 2. Effects of GD17–20 CPF exposure on (A) DA content and (B) turnover. ANOVA across treatment,
region, and sex: (A), treatment, p < 0.04; treatment × region, p < 0.02; (B), treatment, p < 0.007; treatment ×
region, p < 0.02.
*Individual treatments and regions are signiﬁcantly different; values are shown combined for males and females because
of the lack of treatment × sex interactions.
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Figure 3. Effects of PN1–4 CPF (1 mg/kg) exposure on (A) 5HT content and (B) turnover. ANOVA across
treatment, region, and sex: (A), treatment × sex, p < 0.04; male, not signiﬁcant; female, p < 0.03; (B), treat-
ment, p < 0.0001 (separate ANOVAs for males and females were not evaluated because of the lack of a
treatment × sex interaction). Separate ANOVAs were not conducted for each region because of the
absence of treatment × region interactions.
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Figure 4. Effects of PN11–14 CPF (5 mg/kg) exposure on (A) 5HT content and (B) turnover. ANOVA across
treatment, region, and sex: not significant. Separate ANOVAs were not conducted for each region
because of the absence of treatment × region interactions; similarly, values are shown combined for
males and females because of the lack of treatment × sex interactions.
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)circuits provides the most likely explanation
for the effects of CPF on developing 5HT sys-
tems. If 5HT projections do not innervate the
appropriate postsynaptic cells, then receptor
up-regulation will occur because of the lack of
neurotransmitter stimulation, and at the same,
presynaptic neurons will be hyperactive as an
attempt to compensate for the de facto lack of
5HT effect. With miswiring, these compensa-
tions cannot overcome the underlying archi-
tectural problem, leading to behavioral deﬁcits
resembling 5HT deﬁciencies as seen in animal
models of depression (Aldridge et al. 2005a).
Indeed, these types of circuitry defects also
occur with prenatal xenobiotic insults that tar-
get cholinergic systems. Both phenobarbital
and heroin disrupt the regional architecture of
acetylcholine projections in the hippocampus,
leading to parallel increases in cholinergic
receptors, acetylcholine release, and expression
of the presynaptic choline transporter, accom-
panied by behavioral and signaling defects that
are not rectiﬁed by the combined presynaptic/
postsynaptic up-regulation (Steingart et al.
1998; Vatury et al. 2004; Yanai et al. 2004). If
this interpretation is correct, deﬁcits of 5HT
function elicited by developmental exposure
to CPF will also prove to be refractory to
drugs that typically restore 5HT function,
such as the 5HT reuptake inhibitors, resulting
in drug-resistant depression. This possibility
certainly deserves future examination.
Our findings also support the idea that
CPF is frankly neurotoxic in the developing
brain. We found decrements of 5HT levels in
both males and females given the higher CPF
dose on GD17–20 and also for the PN1–4
regimen in females. Nevertheless, the effects
on 5HT turnover occurred at a dose below
that required for loss of transmitter, suggesting
that the miswiring effect is distinct from out-
right neurotoxicity. The effects on 5HT levels
were also evident in the hippocampus, a
region that we found in earlier work to be
highly targeted for CPF-induced cellular dam-
age and similar defects in cholinergic projec-
tions (Qiao et al. 2003, 2004; Slotkin et al.
2001). In keeping with this, the present results
showed prominent loss of hippocampal DA
even at 1 mg/kg, a dose devoid of maternal or
fetal toxicity or fetal cholinesterase inhibition
(Garcia et al. 2003; Qiao et al. 2002). In pre-
vious work we found only minor effects on
DA levels with CPF treatment on PN1–4, and
no such effects with the PN11–14 regimen
(Slotkin et al. 2002), indicating early neonatal
closing of the window of vulnerability for
these particular neurotoxic events. Although
hippocampal DA levels are lower than in the
other regions, the loss of these projections is
likely to play an important role in behavioral
alterations. DA projections provide important
regulatory inputs to hippocampal cholinergic
synapses, with consequent effects on learning
and memory (Yanai et al. 1993). Like the
effects on 5HT turnover, we also found
increased DA turnover after prenatal CPF
exposure, with closure of the window of vulner-
ability in the second postnatal week (Slotkin
et al. 2002). The effects on 5HT thus represent
one component of a larger spectrum of CPF-
induced disruption of synaptic development
and function that ultimately contribute to
behavioral anomalies.
There are two additional features of the
present results that are worth noting. First,
with gestational CPF exposure, the loss of
5HT spared the striatum and similarly,
whereas the hippocampus showed 40–50%
loss of DA, there was no corresponding stri-
atal decrement. Effectively, this regional dif-
ference de-emphasizes the importance of
oxidative stress as a contributory mechanism
for the neurotoxic actions of CPF because the
striatum is typically more sensitive to such
effects than other regions, largely due to its
high content of DA, an oxidative neuro-
transmitter (Bagchi et al. 1995; Crumpton
et al. 2000; Gupta 2004; Karen et al. 2001;
Qiao et al. 2005). Indeed, we recently evalu-
ated lipid peroxidation with each of the CPF
regimens used here and found little or no evi-
dence for oxidative damage with the GD17–20
or PN1–4 regimens, although lipid peroxida-
tion was readily detected after exposure on
PN11–14 (Slotkin et al. 2005). Apparently,
other, non-cholinesterase-related actions of
CPF are more important contributors to neu-
robehavioral teratogenicity in the critical peri-
natal period in which 5HT systems are
especially vulnerable (Barone et al. 2000;
Casida and Quistad 2004; Gupta 2004; Pope
1999; Qiao et al. 2002, 2003; Yanai et al.
2002), although oxidative stress may be rela-
tively more important for later postnatal expo-
sures. The second interesting characteristic is
the relative lack of sex selectivity to the effects
on 5HT turnover, whereas effects on behavior
and 5HT receptor expression show distinct sex
differences (Aldridge et al. 2004, 2005a). In
fact, many of the functional consequences of
CPF exposure represent the elimination of nor-
mal sex differences in synaptic function and
behavior, partially masculinizing the patterns
in females but feminizing males (Aldridge et al.
2004, 2005a). Accordingly, CPF may interfere
with sexual differentiation of the brain, which
peaks during the vulnerable perinatal period
found here (MacLusky and Naftolin 1981;
McCarthy 1994); as a consequence, even
where CPF effects on males and females might
be the same in regard to alterations of 5HT
synaptic activity and/or miswiring of 5HT cir-
cuits, the outcome nevertheless can be
expressed differently for males and females
because of CPF’s effects on sexual differentia-
tion. Again, future studies should enable us to
establish whether this explanation is correct.
In conclusion, the present results reinforce
the concept that developmental CPF exposure,
at doses below the threshold for maternal or
fetal/neonatal toxicity, and below that required
for inhibition of fetal brain cholinesterase, nev-
ertheless causes lasting disruption of 5HT
synaptic activity when exposure occurs in a
critical developmental window centered
around the immediate perinatal period. In
combination with earlier studies of static
synaptic protein biomarkers and 5HT-related
behaviors (Aldridge et al. 2004, 2005a), the
increase in 5HT turnover seen here suggests
strongly that CPF acts through architectural
miswiring of 5HT circuits, resulting in func-
tional deﬁcits despite global up-regulation of
presynaptic and postsynaptic sensitivity. The
developmental neuroteratogenicity of CPF
thus encompasses neurotransmitter systems
beyond those involving acetylcholine, and the
effects seen here for 5HT and DA are likely to
contribute to the emergence of behavioral
alterations in adolescence and adulthood
(Aldridge et al. 2005a; Carr et al. 2001; Dam
et al. 2000; Icenogle et al. 2004; Levin et al.
2001, 2002; Ricceri et al. 2003).
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